Table 1 Patient characteristics (safety-analysis set)

Sex

 Male

102 (61.45)

29 (80.56)

93 (63.70)

890 (63.53)

113 (65.32)

400 (51.41)

 Female

64 (38.55)

7 (19.44)

53 (36.30)

511 (36.47)

60 (34.68)

378 (48.59)

Age [years], mean ± standard deviation

68.3 ± 12.3

66.4 ± 13.0

68.4 ± 14.2

65.3 ± 12.7

62.7 ± 12.6

65.7 ± 13.5

Hospital visit

 Inpatient

10 (6.02)

5 (13.89)

18 (12.33)

29 (2.07)

15 (8.67)

47 (6.04)

 Outpatient

156 (93.98)

31 (86.11)

128 (87.67)

1372 (97.93)

158 (91.33)

731 (93.96)

Primary cause of kidney failure^a

 Diabetic nephropathy

72 (43.37)

19 (52.78)

78 (53.42)

578 (41.26)

61 (35.26)

299 (38.43)

 Chronic glomerulonephritis^b

31 (18.67)

7 (19.44)

14 (9.59)

362 (25.84)

52 (30.06)

164 (21.08)

 Nephrosclerosis

33 (19.88)

9 (25.00)

42 (28.77)

210 (14.99)

39 (22.54)

155 (19.92)

 Polycystic kidney

2 (1.20)

0 (0.00)

7 (4.79)

62 (4.43)

6 (3.47)

48 (6.17)

 Unknown

19 (11.45)

2 (5.56)

7 (4.79)

149 (10.64)

13 (7.51)

92 (11.83)

 Others

15 (9.04)

0 (0.00)

10 (6.85)

85 (6.07)

6 (3.47)

60 (7.71)

Dialysis vintage [year]

 < 0.5

20 (12.05)

8 (22.22)

0 (0.00)

147 (10.49)

37 (21.39)

0 (0.00)

 0.5 to < 1

19 (11.45)

3 (8.33)

0 (0.00)

173 (12.35)

29 (16.76)

0 (0.00)

 1 to < 3

31 (18.67)

17 (47.22)

0 (0.00)

275 (19.63)

50 (28.90)

0 (0.00)

 3 to < 5

23 (13.86)

3 (8.33)

0 (0.00)

191 (13.63)

37 (21.39)

0 (0.00)

 5 to < 10

37 (22.29)

5 (13.89)

0 (0.00)

319 (22.77)

19 (10.98)

0 (0.00)

 10 to < 20

23 (13.86)

0 (0.00)

0 (0.00)

219 (15.63)

1 (0.58)

0 (0.00)

 ≥ 20

12 (7.23)

0 (0.00)

0 (0.00)

77 (5.50)

0 (0.00)

0 (0.00)

 Unknown

1 (0.60)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

 Never

0 (0.00)

0 (0.00)

146 (100.00)

0 (0.00)

0 (0.00)

778 (100.00)

Complications

 Cardiovascular disease

166 (100.00)

36 (100.00)

146 (100.00)

1133 (80.87)

156 (90.17)

706 (90.75)

 No comorbidities other than cardiovascular disease

3 (1.81)

0 (0.00)

3 (2.05)

100 (7.14)

11 (6.36)

39 (5.01)

 Comorbidities present in addition to cardiovascular disease

163 (98.19)

36 (100.00)

143 (97.95)

1298 (92.65)

162 (93.64)

739 (94.99)

 Gastrointestinal disease

112 (67.47)

21 (58.33)

56 (38.36)

719 (51.32)

72 (41.62)

225 (28.92)

 Hepatic disease

20 (12.05)

4 (11.11)

9 (6.16)

81 (5.78)

10 (5.78)

50 (6.43)

 Metabolic disease

131 (78.92)

34 (94.44)

135 (92.47)

979 (69.88)

145 (83.82)

690 (88.69)

 Other disease

155 (93.37)

36 (100.00)

133 (91.10)

1181 (84.30)

146 (84.39)

607 (78.02)

Concomitant medication

 No

0 (0.00)

0 (0.00)

1 (0.68)

4 (0.29)

0 (0.00)

8 (1.03)

 Yes

166 (100.00)

36 (100.00)

145 (99.32)

1397 (99.71)

173 (100.00)

770 (98.97)

Hyperphosphatemia agent

 No

61 (36.75)

11 (30.56)

113 (77.40)

476 (33.98)

71 (41.04)

566 (72.75)

 Yes

105 (63.25)

25 (69.44)

33 (22.60)

925 (66.02)

102 (58.96)

212 (27.25)

Hyperparathyroidism secondary agent

 No

29 (17.47)

6 (16.67)

90 (61.64)

268 (19.13)

35 (20.23)

407 (52.31)

 Yes

137 (82.53)

30 (83.33)

56 (38.36)

1133 (80.87)

138 (79.77)

371 (47.69)

Erythropoiesis-stimulating agent

 No

17 (10.24)

1 (2.78)

23 (15.75)

100 (7.14)

3 (1.73)

102 (13.11)

 Yes

149 (89.76)

35 (97.22)

123 (84.25)

1301 (92.86)

170 (98.27)

676 (86.89)

Gastric acid secretion inhibitor

 No

43 (25.90)

13 (36.11)

76 (52.05)

570 (40.69)

91 (52.60)

481 (61.83)

 Yes

123 (74.10)

23 (63.89)

70 (47.95)

831 (59.31)

82 (47.40)

297 (38.17)

Iron preparation

 No

118 (71.08)

33 (91.67)

134 (91.78)

1040 (74.23)

158 (91.33)

710 (91.26)

 Yes

48 (28.92)

3 (8.33)

12 (8.22)

361 (25.77)

15 (8.67)

68 (8.74)

Others

 No

7 (4.22)

2 (5.56)

4 (2.74)

132 (9.42)

26 (15.03)

65 (8.35)

 Yes

159 (95.78)

34 (94.44)

142 (97.26)

1269 (90.58)

147 (84.97)

713 (91.65)

Dose of FC [mg/day], mean ± standard deviation

1054.5 ± 516.3

951.0 ± 456.6

896.9 ± 524.1

1082.6 ± 510.7

976.4 ± 509.0

845.5 ± 417.3